GAMMA-GLUTAMYL TRANSPEPTIDASE ALTERATION AS A BIOMARKER OF OXIDATIVE STRESS IN PATIENTS WITH HUMAN PAPILLOMAVIRUS LESIONS FOLLOWING TOPICAL TREATMENT WITH SINECATECHINS
ILINCA NICOLAE 1#, MIRCEA TAMPA 1,2#*, CRISTINA MITRAN 1#, CORINA DANIELA ENE 3#, MĂDĂLINA MITRAN 1#, CLARA MATEI 2#, ALINA MUŞETESCU 1#, SILVIU PIȚURU 2#, CORINA SILVIA POP 4#, SIMONA-ROXANA GEORGESCU 1,2#
1.“Victor Babeş” Clinical Hospital for Infectious Diseases, Bucharest, Romania
2.“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3.“Carol Davila” Nephrology Hospital, Bucharest, Romania
4.Emergency University Hospital, Bucharest, Romania
Download Full Article PDF
Human papillomavirus (HPV) penetrates the skin or mucous membranes and in most cases undergoes a natural clearance of virus, pertaining to various factors such as skin integrity and efficacy of the immune response. However, in persistent cases that escape the natural clearance mechanism, the infection leads to the development of skin and mucous lesions, including warts. Sinecatechins, an extract of green tea leaves from Camellia sinensis, is a newly approved therapeutic agent with recently proved efficacy in the treatment of warts. While the mechanism of action is not yet fully understood, it has been postulated that sinecatechins exhibit not only antiviral/antitumour activity, but also an antioxidant action contributing to its effectiveness. This study was conducted to evaluate the oxidative stress biomarkers before and after the treatment with 10% sinecatechins ointment in patients with cutaneous and genital warts. There were assessed the oxidative status (TOS), the antioxidative status (TAS), oxidative stress index (OSI) and gamma-glutamyl transpeptidase (GGT) activity as biomarkers of oxidative stress both before and after the topical treatment in patients with HPV lesions (n = 35) as well as in normal controls (n = 35). We have also assessed the correlations between GGT activity and the level of oxidative stress biomarkers. There were not registered significant changes in GGT level (U/L: 29.1 ± 15.9 vs. 20.8 ± 6.2, p > 0.05), TOS level (µmol H2O2 equivalent/L serum: 3.10 ± 0.29 vs. 3.08 ± 0.22, p > 0.05), and TAS level (µmol Trolox equivalent/L: 1.61 ± 0.31 vs. 1.68 ± 0.26, p > 0.05), accompanied by a statistically significant reduction in OSI level (1.93 ± 0.61 vs. 1.83 ± 0.46, p < 0.05) at the end of the treatment, compared to baseline values. A positive correlation between OSI and GGT in patients with HPV lesions prior to the initiation of treatment (r = 0.312, p < 0.05) was noticed, as well.
